ABBVIE
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 218
- Registration Number
- NCT04086264
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Real-World Experience Study of Elagolix For the Treatment of Endometriosis in Canada
- Conditions
- Endometriosis
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT04080856
- Locations
- 🇨🇦
IWK Health Center /ID# 213066, Halifax, Nova Scotia, Canada
🇨🇦Strand Clinic /ID# 213567, St. John's, Newfoundland and Labrador, Canada
🇨🇦Jessima R&D Inc. /ID# 212943, Lasalle, Quebec, Canada
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
- Conditions
- Chronic Kidney Disease (CKD)Secondary Hyperparathyroidism (SHPT)
- Interventions
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 16
- Registration Number
- NCT04064827
- Locations
- 🇺🇸
Seattle Children's Hospital /ID# 162861, Seattle, Washington, United States
🇺🇸Boston Children's Hospital /ID# 162863, Boston, Massachusetts, United States
🇺🇸Duplicate_Levine Children's Specialty Center- Charlotte /ID# 216057, Charlotte, North Carolina, United States
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
- Conditions
- Myeloproliferative Neoplasm
- Interventions
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 85
- Registration Number
- NCT04041050
- Locations
- 🇺🇸
Providence - St. Jude Medical Center /ID# 242558, Fullerton, California, United States
🇺🇸Moores Cancer Center at UC San Diego /ID# 229584, La Jolla, California, United States
🇺🇸City of Hope /ID# 239769, Duarte, California, United States
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
- Conditions
- Functional ConstipationIrritable Bowel Syndrome With Constipation
- Interventions
- Drug: PlaceboDrug: Linaclotide
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 438
- Registration Number
- NCT04026113
- Locations
- 🇺🇸
Medclinical Research Partners LLC/ Foundation Pediatrics /ID# 232783, East Orange, New Jersey, United States
🇺🇸University of New Mexico /ID# 233011, Albuquerque, New Mexico, United States
🇺🇸The Children's Hospital at Montefiore /ID# 232638, Bronx, New York, United States
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
- Conditions
- Neovascular Age-related Macular DegenerationWet Macular Degeneration
- Interventions
- Genetic: RGX-314
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 865
- Registration Number
- NCT03999801
- Locations
- 🇺🇸
Retinal Research Institute, LCC, Phoenix, Arizona, United States
🇺🇸Sierra Eye Associates, Reno, Nevada, United States
🇺🇸MidAtlantic Retina, Philadelphia, Pennsylvania, United States
A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT03987958
- Locations
- 🇮🇱
Rambam Health Care Campus /ID# 213355, Haifa, H_efa, Israel
🇮🇱Rabin Medical Center /ID# 213343, Haifa, H_efa, Israel
🇮🇱HaEmek Medical Center /ID# 213370, Afula, HaDarom, Israel
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Chronic Plaque Psoriasis
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 2439
- Registration Number
- NCT03982394
- Locations
- 🇯🇵
Nagoya City University Hospital /ID# 213363, Nagoya shi, Aichi, Japan
🇪🇸Hospital General Universitario Gregorio Maranon /ID# 231664, Madrid, Spain
🇦🇺Premier Specialist /ID# 218158, Kogarah, New South Wales, Australia
A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 341
- Registration Number
- NCT03978520
- Locations
- 🇺🇸
Medvin Clinical Research /ID# 211996, Tujunga, California, United States
🇺🇸Arizona Arthritis & Rheumatology Research, PLLC /ID# 214522, Mesa, Arizona, United States
🇨🇳Shanghai Changhai Hospital /ID# 211819, Shanghai, Shanghai, China
A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: ABBV-3067Drug: Placebo ABBV-3067Drug: Placebo ABBV-2222Drug: ABBV-2222
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 78
- Registration Number
- NCT03969888
- Locations
- 🇸🇰
Univerzitna nemocnica Bratislava Nemocnica Ruzinov /ID# 213596, Bratislava, Slovakia
🇫🇷AP-HP - Hopital Cochin /ID# 212864, Paris, France
🇺🇸Medical University of South Carolina /ID# 212187, Charleston, South Carolina, United States